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Results

Background
It has been well established that
genomic instability and mutation is a
major hallmark of cancer.1 However,
due to deficiencies in mismatch
repair, most breast tumors do not
display high rates of mutational
burdens compared to other cancers,
suggesting there are alternative
pathways better for evaluating risk of
tumor progression.2,3 Notably, studies
from our team and others have
revealed that cytosol DNA
fragmentation activates DNA sensing
pathways which in turn activate the
innate immune response.4,5
Consequently, our group decided to
investigate molecular determinants of
the c-GAS/STING pathways to see if
defects in the S-DDR pathway may
reveal biomarkers responsible for the
development of intermediate breast
tumors. After running a genetic
screen, we selected NPRL2 as a top
candidate in regulating the S-DDR.
NPRL2 is a primary component of the
GATOR1 complex which has been
linked to tumor suppression through
its inhibitory interaction with
mTORC1.6 Although the definitive
function of NPRL2 and its role in
regulating the S-DDR is unknown, our
preliminary studies showed
interesting results.

Methods
(1) Immunohistochemistry (IHC) to
compare molecular differences in
tissue microarray slides with
breast lesions at various stages
of breast cancer.
(2) Bioinformatic Analysis for
breast cancer samples in TCGA
(3) Generate NPRL2 knockdown
cell lines using lentivirus
(4) q-PCR (to see if NPRL2-/- or
defects in the S-DDR promote
innate immune signaling)
Expression of the following markers
were analyzed:
• STING pathway factors: c-GAS,
STING, CCL5, CXCL10, IFN-beta
PD-L1, CD276

Positive correlation between NPRL2
and CHK1 expression with Triple
Negative Breast Cancer

In breast cancer patient samples, we found reduced
NPRL2 expression in triple negative breast cancer
(TNBC) compared to hormone positive breast cancer.
We also observed a positive correlation between
NPRL2 expression and CHK1 expression, a key DNA
damage kinase regulating genome stability. This data
suggests that NPRL2 may play a previously unknown
role in maintaining proper DNA damage response
and genome integrity in TNBC by regulating key
players in DDR (DNA damage response.)

Reduced NPRL2 expression is associated with an
increase in immune infiltration

In breast cancer cell lines (left) and patient TCGA data
(right), we found reduced NPRL2 expression in basal
like breast cancer (TNBC) compared to hormone
receptor/HER2 positive breast cancer.

Reduced NPRL2 expression in breast
cancer patients is associated with a
worse prognosis

In breast cancer patient TCGA data, we found that
reduced NPRL2 expression in breast tumors is
associated with an increase immune infiltration,
indicating a ‘hot’ immune status of tumors.

In breast cancer patient TCGA data, we found that reduced NPRL2 expression in breast tumors is
associated with an increase infiltration of a variety of immune cells. This data further supports that
NPRL2 deficiency may predict immune responses in breast tumors.
RNA-Seq Expression Analysis

In breast cancer patient TCGA data (right), we found that
reduced NPRL2 expression in breast tumors is associated
with a worse prognosis in breast cancer patients. This
association is not dependent on the breast subtypes. This
data suggests that NPRL2 may play a role in breast tumor
biology regardless of breast cancer types. NPRL2
deficiency could serve as a common target crossing
different breast subtypes.
.
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NPRL2 knockdown induces c-GAS, STING, CCL5,
CXCL10, IFN-beta, PD-L1, CD276.

Conclusions
•
•
•

NPRL2 and CHK1 was positively correlated with TNBC
Expression of NPRL2 was negatively correlated with prognosis of
breast cancer patients
Reduced NPRL2 expression in breast cancer induced innate
immunity
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